Abstract
Thyrotropin (TSH) regulates thyroid cell proliferation and function through cAMP-mediated signaling pathways that activate protein kinase A (PKA) and Epac/Rap1. The respective roles of PKA versus Epac/Rap1 in TSH signaling remain unclear. We set out to determine whether PKA and/or Rap1 mediate extracellular signal-regulated kinase (ERK) activation by TSH. Neither blocking Rap1 activity nor silencing the expression of Rap1 impaired TSH or forskolin-induced ERK activation in Wistar rat thyroid cells. Direct activation of Epac1 failed to stimulate ERK activity in starved cells, suggesting that Epac-induced Rap1 activity is not coupled to ERK activation in rat thyroid cells. By contrast, PKA activity was required for cAMP-stimulated ERK phosphorylation and was sufficient to increase ERK phosphorylation in starved cells. Expression of dominant-negative Ras inhibited ERK activation by TSH, forskolin, and N6-monobutyryl (6MB)-cAMP, a selective activator of PKA. Silencing the expression of B-Raf also inhibited ERK activation by TSH, forskolin, and 6MB-cAMP, but not that stimulated by insulin or serum. Depletion of B-Raf impaired TSH-induced DNA synthesis, indicating a functional role for B-Raf in TSH-regulated proliferation. Collectively, these results position PKA, Ras, and B-Raf as upstream regulators of ERK activation and identify B-Raf as a selective target of cAMP-elevating agents in thyroid cells. These data provide the first evidence for a functional role for B-Raf in TSH signaling.
- TSH, thyrotropin
- EcAMP, 8-(4-chlorophenylthio)-2′-O-methyl-cAMP
- Epac, exchange protein activated by cAMP
- ERK, extracellular signal-regulated kinase
- PKA, protein kinase A
- PKI, heat-stable protein kinase A inhibitor
- WRT, Wistar rat thyroid
- 6MB-cAMP, N6-monobutyryl-cAMP
- WRT, Wistar rat thyroid
- MEK, mitogen-activated protein kinase kinase
- HA, hemagglutinin
- siRNA, short interfering RNA
- U0126, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene.
Footnotes
-
This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK55757] and the National Institutes of Health National Cancer Institute Cancer Education and Career Development Program, Training Program in Cancer Pharmacology [Grant 5R25-CA101871].
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.109.060129
-
ABBREVIATIONS:
-
↵1 Current affiliation: Trait Discovery-Insect Control DuPont Experimental Station, Wilmington, Delaware.
- Received August 7, 2009.
- Accepted August 31, 2009.
- © 2009 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|